文源 | 源媒汇作者 | 胡青木编辑 | 苏淮春分刚过,北京经济开发区内,一场颠覆性的合作正在破土萌芽。康泰生物与阿斯利康这对“疫情战友”再度携手,宣布以各50%的股权比例,创立总投资4亿美元的合资公司。这不仅是阿斯利康在华首个疫苗生产基地,更标志着中国疫苗企业与国际药企的合作模式发生了巨大转变。回顾行业合作历史,此前跨国药企与中国本土疫苗企业的合作多采用“代理”模式。以默沙东与智飞生物在HPV等...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.